Literature DB >> 26241947

Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient mice.

Hiroyuki Yokote1, Yasuhiko Shinmura2, Tomomi Kanehara1, Shinichi Maruno1, Masahiko Kuranaga1, Hajime Matsui1, So Hashizume3.   

Abstract

BACKGROUND: Attenuated vaccinia virus strain, LC16m8, defective in the B5R envelope protein gene, is used as a stockpile smallpox vaccine strain in Japan against bioterrorism: the defect in the B5R gene mainly contributes to its highly attenuated properties.
METHODS: The protective activity of LC16m8 vaccine against challenge with a lethal dose of vaccinia Western Reserve strain was assessed in wild-type and immunodeficient mice lacking CD4, MHC class I, MHC class II or MHC class I and II antigens.
RESULTS: The immunization with LC16m8 induced strong protective activity comparable to that of its parent strain, Lister (Elstree) strain, in wild-type mice from 2 days to 1 year after vaccination, as well as in immunodeficient mice at 2 or 3 weeks after vaccination. These results implicated that the defect in the B5R gene hardly affected the potential activity of LC16m8 to induce innate, cell-mediated and humoral immunity, and that LC16m8 could be effective in immunodeficient patients.
CONCLUSION: LC16m8 with truncated B5 protein has an activity to induce immunity, such as innate immunity and subsequent cell-mediated and humoral immunity almost completely comparable to the activity of its parental strain Lister.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Bioterrorism; Efficacy evaluation study; Immunodeficient subject; LC16m8; Smallpox vaccine; WHO stockpile vaccine

Mesh:

Substances:

Year:  2015        PMID: 26241947     DOI: 10.1016/j.vaccine.2015.07.076

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  An increase in glycoprotein concentration on extracellular virions dramatically alters vaccinia virus infectivity and pathogenesis without impacting immunogenicity.

Authors:  Stephanie R Monticelli; Peter Bryk; Matthew G Brewer; Hector C Aguilar; Christopher C Norbury; Brian M Ward
Journal:  PLoS Pathog       Date:  2021-12-28       Impact factor: 6.823

Review 2.  Defending against smallpox: a focus on vaccines.

Authors:  Emily A Voigt; Richard B Kennedy; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2016-04-28       Impact factor: 5.217

3.  40 Years without Smallpox.

Authors:  G A Shchelkunova; S N Shchelkunov
Journal:  Acta Naturae       Date:  2017 Oct-Dec       Impact factor: 1.845

Review 4.  Challenges and Achievements in Prevention and Treatment of Smallpox.

Authors:  Sharon Melamed; Tomer Israely; Nir Paran
Journal:  Vaccines (Basel)       Date:  2018-01-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.